Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Whitehawk Therapeutics, Inc. (WHWK : NSDQ)

• Company Description    Aadi Bioscience Inc. is a clinical-stage biopharmaceutical company. It focuses on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Aadi Bioscience Inc., formerly known as Aerpio Pharmaceuticals Inc., is based in LOS ANGELES. Number of Employees: 40

• Price / Volume Information    Yesterday's Closing Price: $1.97 Daily Weekly Monthly 20 Day Moving Average: 138,845 shares Shares Outstanding: 47.11 (millions) Market Capitalization: $92.81 (millions) Beta: 0.55 52 Week High: $3.81 52 Week Low: $1.21 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.43% -7.05% 12 Week 25.48% 5.54% Year To Date -37.56% -41.53%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 HEADQUARTERS PLAZA EAST BUILDING 11TH FLOOR - MORRISTOWN,NJ 7960 USA ph: 551-321-2234 fax: - ir@whitehawktx.com https://ir.whitehawktx.com

• General Corporate Information    Officers David J. Lennon - Chief Executive Officer and President Caley Castelein - Chairman Scott Giacobello - Chief Financial Officer Anupam Dalal - Director Neil Desai - Director Peer Information Whitehawk Therapeutics, Inc. (CORR.) Whitehawk Therapeutics, Inc. (RSPI) Whitehawk Therapeutics, Inc. (CGXP) Whitehawk Therapeutics, Inc. (BGEN) Whitehawk Therapeutics, Inc. (GTBP) Whitehawk Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00032Q104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/06/25 Share - Related Items Shares Outstanding: 47.11 Most Recent Split Date: 8.00 (0.07:1) Beta: 0.55 Market Capitalization: $92.81 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.29 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.03 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.42 Price/Cash Flow: - Price / Sales: 3.34 EPS Growth vs. Year Ago Period: 47.06% vs. Previous Quarter: 46.27% Sales Growth vs. Year Ago Period: 33.48% vs. Previous Quarter: -1.30% ROE 06/30/25 - - 03/31/25 - -56.73 12/31/24 - -87.67 ROA 06/30/25 - - 03/31/25 - -48.68 12/31/24 - -69.10 Current Ratio 06/30/25 - - 03/31/25 - 18.95 12/31/24 - 3.59 Quick Ratio 06/30/25 - - 03/31/25 - 18.95 12/31/24 - 3.28 Operating Margin 06/30/25 - - 03/31/25 - -215.41 12/31/24 - -245.13 Net Margin 06/30/25 - - 03/31/25 - 99.42 12/31/24 - -245.13 Pre-Tax Margin 06/30/25 - - 03/31/25 - 99.42 12/31/24 - -245.13 Book Value 06/30/25 - - 03/31/25 - 4.74 12/31/24 - 2.12 Inventory Turnover 06/30/25 - - 03/31/25 - 0.74 12/31/24 - 0.53 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©